FDA Refuses To File BLA For Cancer Gene Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Advexin setback compounds dicey financial status of developmental company Introgen.
You may also be interested in...
The Unlikely Renaissance Of Gene Therapy
After a decade of doubts, fears, and scares, advances in gene therapy have brought one drug close to approval, and a few venture-backed start-ups are gaining momentum. Is it enough to persuade more VCs to jump in?
Introgen Restructures To Ready For Advexin Approval Process
New manufacturing unit could profit from pickup in gene-therapy business.
Introgen Files Advexin For Head And Neck Cancer In U.S., EU
Biotech says it hopes to follow the Idec/Rituxan model in bringing oncologic gene therapy to the U.S. market.